NRXP NRX Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1719406 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,076.5%
TTM net income YoY48.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin40.5%
Operating margin-551.7%
Net margin-454.1%
FCF margin—
EBITDA margin-546.4%
Returns
ROE—
ROA-92.3%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets107.1%
Debt / equity—
Current ratio0.76x
Interest coverage-17.37x
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio17.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2024Q32025-09-30 | 2024Q22025-06-30 | 2024Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.16M | $1.10M | $1.07M | $1.02M | $200,000 | $0 | $0 | $0 |
| Cost of revenue | $874,000 | $675,000 | $631,000 | $408,000 | $97,000 | $0 | $0 | $0 |
| Gross profit | $285,000 | $426,000 | $437,000 | $617,000 | $103,000 | $0 | $0 | $0 |
| R&D expense | $1.81M | $2.12M | $1.31M | $558,000 | $1.43M | $987,000 | $804,000 | $1.04M |
| SG&A expense | $6.56M | $4.75M | $3.81M | $4.57M | $2.81M | $2.74M | $2.94M | $2.60M |
| Operating income | -$8.14M | -$6.50M | -$4.74M | -$4.62M | -$4.02M | -$3.73M | -$3.85M | -$2.43M |
| Interest expense | $239,000 | $240,000 | $233,000 | $671,000 | $0 | $0 | $0 | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.17M | -$16.52M | -$1.43M | $360,000 | -$5.89M | -$17.58M | -$5.51M | -$9.08M |
| EBITDA | -$8.08M | -$6.44M | -$4.68M | -$4.58M | -$4.00M | -$3.73M | -$3.85M | -$2.43M |
| EPS (basic) | -0.05 | -0.44 | -0.04 | — | -0.27 | -0.98 | -0.34 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $19.82M | $26.69M | $6.71M | $7.80M | $7.18M | $2.91M | $5.55M | $1.44M |
| Receivables | $218,000 | $206,000 | $181,000 | $161,000 | $239,000 | — | — | $0 |
| Current assets | $22.21M | $29.16M | $7.36M | $8.89M | $11.95M | $4.59M | $7.26M | $3.30M |
| PP&E, net | $901,000 | $919,000 | $259,000 | $63,000 | $69,000 | — | — | $10,000 |
| Goodwill | $2.35M | $1.79M | $1.79M | $1.79M | $610,000 | — | — | $0 |
| Intangibles | $787,000 | $832,000 | $879,000 | $925,000 | $1.78M | — | — | $0 |
| Total assets | $27.82M | $34.16M | $11.90M | $12.96M | $15.00M | $4.84M | $7.59M | $3.65M |
| Current liabilities | $29.25M | $33.87M | $25.18M | $28.58M | $40.59M | $40.45M | $32.75M | $21.86M |
| Total liabilities | $29.80M | $34.33M | $25.72M | $28.89M | $40.75M | $40.45M | $32.75M | $26.87M |
| Shareholders' equity | -$1.99M | -$170,000 | -$13.82M | -$15.94M | -$25.75M | -$35.62M | -$25.16M | -$23.22M |
| Shares outstanding | 43.21M | 43.16M | 33.47M | 31.73M | 27.68M | 19.47M | 17.12M | 14.59M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.71M | -$8.88M | -$4.29M | -$3.71M | -$2.89M | -$4.03M | -$3.48M | -$2.10M |
| Capital expenditure | -$1,000 | — | — | — | $0 | $0 | $0 | $0 |
| Free cash flow | -$6.71M | — | — | — | -$2.89M | -$4.03M | -$3.48M | -$2.10M |
| Investing cash flow | $1,000 | -$684,000 | -$213,000 | -$249,000 | -$2.56M | $0 | $0 | $0 |
| Financing cash flow | -$152,000 | $29.53M | $3.42M | $4.58M | $9.73M | $1.39M | $7.58M | $1.90M |
| Depreciation & amortization | $62,000 | $66,000 | $63,000 | $42,000 | $26,000 | $0 | $1,000 | $1,000 |
| Stock-based compensation | $188,000 | $139,000 | $151,000 | $81,000 | $68,000 | $67,000 | $12,000 | $43,000 |
Free plan shows the latest 8 periods; Pro shows all 36 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.